Exchange
KOSDAQ
Every company in the roster listed on KOSDAQ.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
24 of 24 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 GI Innovation, Inc.358570 · KOSDAQ | 3 assets: 3 Ph 2 | GI-101Phase 1/2 · Non-Small Cell Lung Cancer | Feb 2027GI-108 · Phase 1/2 |
 HK inno.N Corporation195940 · KOSDAQ | 3 assets: 2 Ph 3, 1 Ph 2 | CJ-30060Phase 3 · HypertensionPartial signal | None on record |
 Ahn-Gook Pharmaceutical001540 · KOSDAQ | 2 assets: 2 Ph 3 | AG2304RPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Curacle365270 · KOSDAQ | 2 assets: 2 Ph 2 | CU104Phase 2 · Ulcerative ColitisPartial signal | None on record |
Kainos Medicine284620 · KOSDAQ | 2 assets: 1 Ph 2, 1 Ph 1 | KM-819Phase 2 · Parkinson's DiseasePartial signal | None on record |
 S.Biomedics304360 · KOSDAQ | 2 assets: 2 Ph 2 | Adipose-derived MSC clusters (S.Biomedics)Phase 1/2 · Atherosclerotic Cardiovascular DiseaseWeak signal | 7 Feb 2029TED-A9 (A9-DPC) · |
 Anterogen065660 · KOSDAQ | 1 asset: 1 Ph 3 | Cupistem / ALLO-ASCPhase 3 · Crohn's DiseaseWeak signal | None on record |
 Aptabio Therapeutics293780 · KOSDAQ | 1 asset: 1 Ph 2 | APX-115Phase 2 · Type 2 DiabetesPartial signal | 30 Jun 2027APX-115 · Phase 2 |
 CJ Bioscience, Inc.311690 · KOSDAQ | 1 asset: 1 Ph 2 | CJRB-101Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Enzychem Lifesciences183490 · KOSDAQ | 1 asset: 1 Ph 2 | MosedipimodPhase 2 · Atopic Dermatitis | Oct 2027Mosedipimod · Phase 2 |
 GemVax & KAEL082270 · KOSDAQ | 1 asset: 1 Ph 3 | GV1001Phase 3 · Alzheimer's DiseasePartial signal | None on record |
 Helixmith Co., Ltd.084990 · KOSDAQ | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 Huons084110 · KOSDAQ | 1 asset: 1 Ph 1 | HUC2-676Phase 1 · Obesity | None on record |
 IntoCell, Inc287840 · KOSDAQ | 1 asset: 1 Ph 1 | ITC-6146ROPhase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027ITC-6146RO · Phase 1 |
 Kangstem Biotech217730 · KOSDAQ | 1 asset: 1 Ph 3 | Furestem-CDPhase 3 · Crohn's DiseaseWeak signal | None on record |
 LigaChem Biosciences, Inc.141080 · KOSDAQ | 1 asset: 1 Ph 2 | LCB84Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027LCB84 · Phase 1/2 |
 Nature Cell Co., Ltd.007390 · KOSDAQ | 1 asset: 1 Ph 2 | AstroStemPhase 2 · Alzheimer's DiseasePartial signal | None on record |
 Oscotec Inc.039200 · KOSDAQ | 1 asset: 1 Ph 1 | OCT-598Phase 1 · Non-Small Cell Lung Cancer | Dec 2027OCT-598 · Phase 1 |
 Parataxis Korea, Inc.288330 · KOSDAQ | 1 asset: 1 Ph 2 | BBT-207Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Peptron087010 · KOSDAQ | 1 asset: 1 Ph 2 | PT320Phase 2 · Parkinson's DiseasePartial signal | None on record |
 SCM Lifescience298060 · KOSDAQ | 1 asset: 1 Ph 2 | SCM-AGHPhase 1/2 · Atopic DermatitisPartial signal | None on record |
 STCube, Inc.052020 · KOSDAQ | 1 asset: 1 Ph 2 | NelmastobartPhase 2 · Non-Small Cell Lung Cancer | 31 Aug 2027Nelmastobart · Phase 2 |
 Shaperon378800 · KOSDAQ | 1 asset: 1 Ph 2 | HY209gelPhase 2 · Atopic DermatitisPartial signal | None on record |
 Voronoi, Inc310210 · KOSDAQ | 1 asset: 1 Ph 2 | VRN110755Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2029VRN110755 · Phase 1/2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).